CARBIDOPA, LEVODOPA AND ENTACAPONE
Clinical safety rating: safe
Nonselective MAOIs are contraindicated and pyridoxine can reverse its effects in the periphery Can cause orthostatic hypotension and hallucinations.
Levodopa is a precursor to dopamine that crosses the blood-brain barrier and is converted to dopamine by aromatic L-amino acid decarboxylase, replenishing depleted dopamine in the striatum. Carbidopa inhibits peripheral decarboxylation of levodopa, increasing its availability to the brain and reducing peripheral side effects. Entacapone is a selective and reversible inhibitor of catechol-O-methyltransferase (COMT), primarily in the periphery, which prolongs the half-life and duration of action of levodopa by reducing its conversion to 3-O-methyldopa.
| Metabolism | Levodopa is extensively metabolized by aromatic L-amino acid decarboxylase and catechol-O-methyltransferase (COMT). Carbidopa is metabolized by oxidation and glucuronidation. Entacapone is metabolized via glucuronidation (primarily UGT1A9) and to a lesser extent by methylation; its metabolites are inactive. |
| Excretion | Levodopa: renal excretion of metabolites (dopamine, DOPAC, HVA) and unchanged drug (<1%); carbidopa: 70% renal as unchanged drug and metabolites; entacapone: 90% fecal (biliary), 10% renal. |
| Half-life | Levodopa: 1-2 hours (short half-life necessitates frequent dosing with carbidopa to inhibit peripheral decarboxylation). Carbidopa: 2-3 hours. Entacapone: 1-2 hours (terminal half-life prolonged with levodopa). Clinical context: entacapone prolongs levodopa's half-life by inhibiting COMT. |
| Protein binding | Levodopa: 10-20% (negligible). Carbidopa: 36% (albumin). Entacapone: 98% (mainly albumin). |
| Volume of Distribution | Levodopa: 0.9-1.4 L/kg (widely distributed, including CNS). Carbidopa: 0.8 L/kg (limited to peripheral tissues). Entacapone: 0.5 L/kg (low Vd, confined to plasma and extracellular fluid). |
| Bioavailability | Levodopa: 70-95% (with carbidopa; reduced to 40-70% without carbidopa due to peripheral decarboxylation). Carbidopa: 40-50% (oral). Entacapone: 35-40% (oral, high first-pass metabolism). |
| Onset of Action | Oral: levodopa effect in 30-60 minutes; entacapone reduces wearing-off but has no direct motor effect; carbidopa does not cross BBB, onset not applicable. |
| Duration of Action | Oral levodopa: 3-6 hours (with carbidopa). Entacapone: prolongs levodopa duration by 1-2 hours. Clinical note: twice-daily or three-times-daily dosing for combination. |
One tablet (carbidopa 25 mg/levodopa 100 mg/entacapone 200 mg) orally up to a maximum of 8 tablets per day in divided doses. Optimal dose individualized based on response and tolerance.
| Dosage form | TABLET |
| Renal impairment | GFR 30-50 mL/min: Use with caution; monitor for adverse effects. GFR <30 mL/min: Not recommended. |
| Liver impairment | Child-Pugh Class A: No adjustment required. Child-Pugh Class B: Entacapone exposure may increase; use with caution. Child-Pugh Class C: Contraindicated. |
| Pediatric use | Safety and efficacy not established in pediatric patients; no specific dosing recommendations available. |
| Geriatric use | Start with lower doses due to increased risk of adverse effects (e.g., hallucinations, dyskinesias, orthostatic hypotension). Titrate slowly. Monitor renal function as GFR declines with age. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Nonselective MAOIs are contraindicated and pyridoxine can reverse its effects in the periphery Can cause orthostatic hypotension and hallucinations.
| FDA category | Animal |
| Breastfeeding | Levodopa is excreted into breast milk; M/P ratio unknown. Carbidopa and entacapone are likely excreted. Potential for adverse effects in infant (e.g., somnolence, poor feeding). Avoid breastfeeding or discontinue drug. |
| Teratogenic Risk | Pregnancy Category C. First trimester: Levodopa crosses placenta; animal studies show visceral and skeletal malformations at high doses. Carbidopa and entacapone have limited human data. Second and third trimesters: Risk of fetal hypoxia due to maternal hypotension; possible premature labor. Avoid use unless benefit outweighs risk. |
■ FDA Black Box Warning
None.
| Common Effects | Nausea |
| Serious Effects |
["Hypersensitivity to carbidopa, levodopa, entacapone, or any component of the formulation","Concurrent use of nonselective monoamine oxidase inhibitors (MAOIs); MAOIs must be discontinued at least 2 weeks prior","Narrow-angle glaucoma (relative contraindication)","History of malignant melanoma (theoretical risk due to levodopa's role in melanin synthesis)","Severe hepatic impairment (Child-Pugh class C) for entacapone component"]
| Precautions | ["May cause or exacerbate dyskinesia and other movement disorders","Risk of hypotension, including orthostatic hypotension","Risk of hallucinations, psychosis, or altered mental status","Impulse control disorders (e.g., pathological gambling, hypersexuality) have been reported","Potential for decreased efficacy over time (wearing-off phenomenon)","May cause gastrointestinal bleeding, especially in patients with history of peptic ulcer disease","Risk of rhabdomyolysis secondary to severe dyskinesias or neuroleptic malignant syndrome (NMS) upon abrupt withdrawal","Caution in patients with cardiovascular disease (e.g., arrhythmias), pulmonary disease, or renal/hepatic impairment"] |
Loading safety data…
| Fetal Monitoring | Monitor maternal blood pressure, heart rate, and extrapyramidal symptoms. Monitor fetal growth and uterine activity. Consider fetal echocardiography if first-trimester exposure. |
| Fertility Effects | Levodopa may decrease prolactin levels, potentially suppressing lactation. No definitive evidence of impaired fertility in humans. In animal studies, no major reproductive toxicity at therapeutic doses. |
| Food/Dietary | High-protein meals can compete with levodopa for absorption, reducing efficacy. Absorption is enhanced when taken on an empty stomach. Avoid iron supplements or multivitamins containing iron within 2 hours of dosing as iron can chelate levodopa. Entacapone absorption is not significantly affected by food. |
| Clinical Pearls | Levodopa is a prodrug converted to dopamine centrally; carbidopa inhibits peripheral decarboxylation, reducing side effects and increasing levodopa availability. Entacapone inhibits COMT, prolonging levodopa half-life. Monitor for dyskinesias, orthostatic hypotension, and neuropsychiatric effects. Dose adjustments needed with hepatic impairment. Avoid abrupt discontinuation. May cause urine discoloration (reddish-brown). |
| Patient Advice | Take exactly as prescribed; do not stop suddenly. · May cause dizziness or fainting; rise slowly from sitting or lying. · Urine, sweat, or saliva may turn reddish-brown; this is harmless. · Avoid high-protein meals as they may reduce drug absorption. · Report worsening of symptoms, involuntary movements, or mood changes. · Use caution when driving until you know how this medication affects you. |